New research directions on disparities in obesity and type 2 diabetes
- PMID: 31793006
- PMCID: PMC7159314
- DOI: 10.1111/nyas.14270
New research directions on disparities in obesity and type 2 diabetes
Abstract
Obesity and type 2 diabetes disproportionately impact U.S. racial and ethnic minority communities and low-income populations. Improvements in implementing efficacious interventions to reduce the incidence of type 2 diabetes are underway (i.e., the National Diabetes Prevention Program), but challenges in effectively scaling-up successful interventions and reaching at-risk populations remain. In October 2017, the National Institutes of Health convened a workshop to understand how to (1) address socioeconomic and other environmental conditions that perpetuate disparities in the burden of obesity and type 2 diabetes; (2) design effective prevention and treatment strategies that are accessible, feasible, culturally relevant, and acceptable to diverse population groups; and (3) achieve sustainable health improvement approaches in communities with the greatest burden of these diseases. Common features of guiding frameworks to understand and address disparities and promote health equity were described. Promising research directions were identified in numerous areas, including study design, methodology, and core metrics; program implementation and scalability; the integration of medical care and social services; strategies to enhance patient empowerment; and understanding and addressing the impact of psychosocial stress on disease onset and progression in addition to factors that support resiliency and health.
Keywords: NIDDK; NIH; diabetes; disparities; obesity; social determinants.
© 2019 New York Academy of Sciences.
Conflict of interest statement
Competing interests
M.H.C. is a consultant to the Patient-Centered Outcomes Research Institute and a member of the National Advisory Council to the National Institute on Minority Health and Health Disparities. M.D.G. is a faculty consultant to the Lifescan Diabetes Institute and Eli Lilly, Co. C.M.M. is a member of the U.S. Preventive Services Task Force. This article does not necessarily represent the views and policies of the U.S. Preventive Services Task Force. D.F.T. is a member of the WW Scientific Advisory Board.
Figures


References
-
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. 2018. National Diabetes Prevention Program; Accessed January 10, 2018 https://www.cdc.gov/diabetes/prevention/index.html.
Publication types
MeSH terms
Grants and funding
- P30 DK092926/DK/NIDDK NIH HHS/United States
- Z99 DK999999/ImNIH/Intramural NIH HHS/United States
- P30 DK111022/DK/NIDDK NIH HHS/United States
- The National Cancer Institute (NCI)/International
- R01 DK121475/DK/NIDDK NIH HHS/United States
- P30 DK056350/DK/NIDDK NIH HHS/United States
- P30 DK092949/DK/NIDDK NIH HHS/United States
- NIH Office of Disease Prevention (ODP)/International
- P30 DK092950/DK/NIDDK NIH HHS/United States
- P30 DK048520/DK/NIDDK NIH HHS/United States
- P30 DK079626/DK/NIDDK NIH HHS/United States
- R18 DK092765/DK/NIDDK NIH HHS/United States